Zimmer Holdings, Inc. (ZMH)

pos +0.00
Today's Range: 110.98 - 111.77 | ZMH Avg Daily Volume: 0
Last Update: 11/26/14 - 4:00 PM EST
Volume: 0
YTD Performance: 0.00%
Open: $0.00
Previous Close: $111.08
52 Week Range: $89.58 - $111.97
Oustanding Shares: 169,354,000
Market Cap: 18,811,842,300
6-Month Chart
TheStreet Ratings Grade for ZMH
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy
Moderate Buy
Moderate Sell
Strong Sell
Mean Rec. 0.00 0.00 0.00 0.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
ZMH Sector Avg. S&P 500
0.00 0.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
Revenue 0.00 0.00 0.00
Net Income 0.00 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ZMH:
Revenue 0.00B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $1.71 $1.53 $6.05 $6.55
Number of Analysts 13 6 17 17
High Estimate $1.71 $1.56 $6.06 $7.79
Low Estimate $1.70 $1.49 $6.05 $6.26
Prior Year $1.66 $1.50 $5.75 $6.05
Growth Rate (Year over Year) 2.78% 1.89% 5.25% 8.17%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Christopher Versace

 | Oct 25, 2014 | 12:00 PM EDT

Americans are living much longer these days -- and there are a number of ways to invest.


David Katz

 | Oct 21, 2014 | 12:30 PM EDT

Investing during a mid-term election can offer large returns.


Christopher Versace

 | Sep 18, 2014 | 11:00 AM EDT

Consider this unsexy but good value play in healthcare. 


David Katz

 | Sep 12, 2014 | 11:44 AM EDT

 Hepatitis C therapies are the pacesetters.

bullishZimmer upgraded at William Blair

Aug 18, 2014 | 7:22 AM EDT

ZMH was upgraded to Outperform, William Blair said. Recent pullback has created a buying opportunity, as the Biomet deal should be accretive to earnings.


David Katz

 | Aug 4, 2014 | 11:27 AM EDT

It's time to start buying selectively during the pullback.

bullishZimmer upgraded at Oppenheimer

Jul 28, 2014 | 7:44 AM EDT

ZMH was upgraded from Perform to Outperform, Oppenheimer said. $118 price target. Biomet deal should add to earnings, beginning in 2015.




David Katz

 | May 16, 2014 | 12:00 PM EDT

Spice up your portfolio with some takeover bait.

bullishZimmer upgraded at Needham

May 14, 2014 | 7:27 AM EDT

ZMH was upgraded from Hold to Strong Buy, Needham said. BMET purchase should add to earnings and both companies can gain market share in the next year. 




David Katz

 | May 9, 2014 | 12:30 PM EDT

Six stocks poised to deliver favorable returns for the balance of the year.

Lights, Camera, ACTION! This move lately in GPRO has been stellar, up nearly 12% over the...
For just under two weeks MCD has been bumping up against a very solid wall of resista...
Texas Instruments is surging today. Shares are up over 2.7% and are moving further i...
Shares of Amazon (AMZN) have been trading within a set of Fibonacci retracements measured ...


Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.